BR0315889A - Method of treating, preventing or controlling macular degeneration and pharmaceutical composition - Google Patents

Method of treating, preventing or controlling macular degeneration and pharmaceutical composition

Info

Publication number
BR0315889A
BR0315889A BR0315889-6A BR0315889A BR0315889A BR 0315889 A BR0315889 A BR 0315889A BR 0315889 A BR0315889 A BR 0315889A BR 0315889 A BR0315889 A BR 0315889A
Authority
BR
Brazil
Prior art keywords
macular degeneration
treating
preventing
pharmaceutical composition
controlling
Prior art date
Application number
BR0315889-6A
Other languages
Portuguese (pt)
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR0315889A publication Critical patent/BR0315889A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"MéTODO DE TRATAR, PREVENIR OU CONTROLAR DEGENERAçãO MACULAR E COMPOSIçãO FARMACêUTICA". São descritos métodos de tratamento, prevenção e/ou controle de degeneração macular. Modalidades específicas incluem a administração de uma droga inibitória de citocina seletiva, ou de um sal, solvato, hidrato, estereoisómero, clatrato, ou pró-droga farmaceuticamente aceitáveis da mesma, sozinha ou em combinação com um segundo agente ativo e/ou cirurgia. Também são descritas composições farmacêuticas, formas de dosagem unitárias individuais, e kits adequados para uso nos métodos da invenção."METHOD OF TREATING, PREVENTING OR CONTROLING MACULAR DEGENERATION AND PHARMACEUTICAL COMPOSITION". Methods of treatment, prevention and / or control of macular degeneration are described. Specific embodiments include administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof alone or in combination with a second active agent and / or surgery. Also disclosed are pharmaceutical compositions, individual unit dosage forms, and kits suitable for use in the methods of the invention.

BR0315889-6A 2002-10-31 2003-10-31 Method of treating, preventing or controlling macular degeneration and pharmaceutical composition BR0315889A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42290002P 2002-10-31 2002-10-31
PCT/US2003/034535 WO2004041181A2 (en) 2002-10-31 2003-10-31 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration

Publications (1)

Publication Number Publication Date
BR0315889A true BR0315889A (en) 2005-10-04

Family

ID=32312567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315889-6A BR0315889A (en) 2002-10-31 2003-10-31 Method of treating, preventing or controlling macular degeneration and pharmaceutical composition

Country Status (12)

Country Link
EP (1) EP1567148A4 (en)
JP (1) JP2006509743A (en)
KR (1) KR20050062649A (en)
CN (1) CN1731997A (en)
AU (1) AU2003285107B2 (en)
BR (1) BR0315889A (en)
CA (1) CA2504263A1 (en)
MX (1) MXPA05004486A (en)
NZ (1) NZ540185A (en)
TW (1) TW200418455A (en)
WO (1) WO2004041181A2 (en)
ZA (1) ZA200503468B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
WO2012096884A1 (en) * 2011-01-10 2012-07-19 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
KR101908330B1 (en) 2017-02-17 2018-10-16 인제대학교 산학협력단 Novel anti-vascular endothelial growth factor antibody and composition for preventing or treating age-related macular degeneration comprising thereof
WO2020113373A1 (en) * 2018-12-03 2020-06-11 Zhuhai Qiwei Bio-Technology Ltd. Method of treating age-related macular degeneration
US20220015338A1 (en) * 2018-11-14 2022-01-20 Zhuhai Qiwei Bio-Technology Ltd. Animal models, screening methods, and treatment methods for intraocular diseases or disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577589A (en) * 1897-02-23 Valve for explosive-engines
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO1995003807A1 (en) * 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
HUP0003761A3 (en) * 1997-07-31 2001-04-28 Celgene Corp Warren Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
CA2331461C (en) * 1998-05-11 2008-10-07 Entremed, Inc. Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
JP2000159761A (en) * 1998-11-30 2000-06-13 Yoshio Takeuchi Fluorothalidomide
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
PL373339A1 (en) * 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
CA2486141A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
ZA200503024B (en) * 2002-10-15 2006-11-29 Celgene Corp Selective cytokine inhibitory drugs for treating myelodysplastic syndrome

Also Published As

Publication number Publication date
TW200418455A (en) 2004-10-01
WO2004041181A3 (en) 2005-02-17
AU2003285107B2 (en) 2008-01-10
CA2504263A1 (en) 2004-05-21
ZA200503468B (en) 2006-10-25
JP2006509743A (en) 2006-03-23
AU2003285107A1 (en) 2004-06-07
NZ540185A (en) 2008-01-31
WO2004041181A2 (en) 2004-05-21
EP1567148A2 (en) 2005-08-31
KR20050062649A (en) 2005-06-23
EP1567148A4 (en) 2010-09-15
MXPA05004486A (en) 2005-07-26
CN1731997A (en) 2006-02-08

Similar Documents

Publication Publication Date Title
BRPI0415971A (en) method for treating, preventing or controlling macular degeneration, and pharmaceutical composition
BRPI0415649A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
BRPI0416260A (en) method for treating, preventing or controlling an asbestos-related disease or disorder and pharmaceutical composition
BR0315593A (en) Method of treating, preventing, modifying or controlling pain and pharmaceutical composition
BRPI0510166A (en) method for treating, preventing or controlling pulmonary hypertension, and pharmaceutical composition
BR0316082A (en) Methods of treating or preventing and controlling a myeloproliferative disease, reducing or preventing an adverse effect associated with the administration of a second active agent in a patient suffering from a myeloproliferative disease and enhancing the therapeutic efficacy of a myeloproliferative disease treatment, composition. pharmaceutical and kit
BRPI0509400A (en) methods for treating or preventing dysfunctional sleep, controlling dysfunctional sleep and improving time to sleep, duration of sleep or quality of sleep, or enhancing ability to get up feeling refreshed after a night's sleep, pharmaceutical composition , and, kit suitable for use in the treatment, prevention or control of dysfunctional sleep
BRPI0510110A (en) method for treating, preventing or controlling pulmonary hypertension, and pharmaceutical composition
BRPI0519030A2 (en) methods of treating, preventing, or controlling inflammation of the airways and of a disease or disorder of the airways or lungs, and pharmaceutical composition
BRPI0510167A (en) method to treat, prevent or control pulmonary hypertension
BRPI0518282A2 (en) use of a therapeutically or prophylactically effective amount of an immunomodulatory compound
BR0316050A (en) Methods of treating, controlling or preventing specific cancer and disease associated with unwanted angiogenesis and reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy, or immunotherapy in a patient. suffering from a specific cancer, pharmaceutical composition and kit
BR0315573A (en) Method for treating, preventing, controlling and / or modifying pain in a patient and pharmaceutical composition.
BRPI0518255A2 (en) Methods of treating or preventing a central nervous system injury to reduce or prevent an adverse effect, and pharmaceutical composition
BR0315316A (en) Methods of treating, preventing or controlling a myelodysplastic syndrome, and reducing or preventing an adverse effect associated with the administration of a second active ingredient to a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, unit dosage form, and kit
BRPI0418742A (en) methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit
BR0315931A (en) Method of treating, preventing or controlling macular degeneration and pharmaceutical composition
BRPI0416275A (en) methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis
BRPI0409884A (en) compounds, pharmaceutical compositions, method for treating or porphyxia of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds
BRPI0519621A2 (en) uses of sabcomelin, a pharmaceutical composition, at least one antimanic agent or mood stabilizer, and a combination of sabcomelin or a pharmaceutically acceptable salt thereof and at least one antimanic agent or mood stabilizer, pharmaceutical composition, kit of parts for use in the treatment of bipolar disorders, sabcomelin, and method of treatment of biopolar disorders
BR0315609A (en) Method of treating, preventing, modifying or controlling pain and pharmaceutical composition
BRPI0518062A (en) use of a pde4 modulator, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and, pharmaceutical composition
BRPI0409818A (en) compounds, pharmaceutical compositions, method for the treatment or prophylaxis of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds
BR0315889A (en) Method of treating, preventing or controlling macular degeneration and pharmaceutical composition
BRPI0415651A (en) methods for treating, preventing, modifying and / or administering fibromyalgia, and for reducing or preventing an adverse effect associated with the administration of a second active ingredient in a fibromyalgia patient, and, pharmaceutical composition.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.